New preclinical findings from extensive cell and animal studies suggest that a drug already used for a rare kidney disease could benefit patients with some mitochondrial disorders -- complex conditions with severe energy deficiency for which no proven effective treatments exist. Future clinical research is needed to explore whether the drug, cysteamine bitartrate, will meaningfully benefit patients.
from Top Health News -- ScienceDaily https://ift.tt/2Ua8jKo
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
It is looking at raising a debt of Rs 450 crore for the Eluru project and Rs 400 crore for the Bengaluru project, the official added from ...
-
With 73,642 new daily recoveries, the most so far, India's recovery rate has improved to 77.32%, while death rate has come down to 1.72%...
-
Modi said political stability through a massive mandate for his government alongside predictable policy provides a unique opportunity for In...
No comments:
Post a Comment